Introduction
Status epilepticus (SE) is a common medical condition with an incidence in the Caucasian population of at least 20/100,000/year. 1 Whereas in generalized convulsive status epilepticus (GCSE) guidelines agree that for the treatment of refractory GCSE after the administration of a benzodiazepine and one other antiepileptic drug (AED) like phenytoin or phenobarbital anesthesia is required, 2 the recommendations for the treatment of nonconvulsive status epilepticus (NCSE) and simple partial motor status epilepticus or epilepsia partialis continua (EPC) are not that straightforward. Especially in EPC any drug effective in chronic epilepsy may be tried. 3 In NCSE with the exception of subtle SE after insufficient treatment of GCSE after failure of first line therapy further nonanaesthetising i.v. substances as levetiracetam, phenobarbital or valproic acid are recommended instead of anaesthetics. 4 Meanwhile four case reports [5] [6] [7] [8] and three case series [9] [10] [11] of patients with refractory SE or periodic epileptiform patterns treated with lacosamide (LCM) have been published. In all case reports successful treatments with LCM were described. Koubeissi et al. 10 reported in their whole group of four patients successful treatments of SE with LCM. In the series of Kellinghaus et al. 9 LCM was the termination drug in 17 of 39 episodes of status epilepticus. In the series of Parkerson et al. 11 12 of 17 patients responded to LCM with improvement in the seizures or the epileptiform activity. Here we present the experience with LCM in the treatment of NCSE and EPC at the university hospital of Rostock, which may provide further evidence concerning the efficacy of LCM in these conditions.
Methods
The data presented here are part of a large ongoing retrospective study, in which we evaluate every status epilepticus treatment at the neurological department of the University of Rostock from 2000 to 2009. This study was approved by the local ethics board at Rostock University under the identifier A 201002. In this study we identify the patients treated in our department by searching for the term ''status epilepticus'' in the electronic archive of medical reports of our clinic. Then we review the medical file of these patients to make out at which time which AED was administered and which AED at which time was effective to terminate the Nonconvulsive status epilepticus (NCSE) and epilepsia partialis continua (EPC) are common epileptic conditions for which straightforward recommendations based on controlled randomized trials for treatment in therapy refractory courses are lacking. In a large retrospective study on drug efficacy in status epilepticus (SE) we identified the patients treated in our department by searching for the term ''status epilepticus'' in the electronic archive of medical reports of our clinic. Here we present the subset of data concerning the patients treated with lacosamide (LCM). Ten episodes of SE in nine patients could be analyzed. To control for age dependency of results at discharge we calculated a Spearman correlation coefficient with age as independent variable and return to baseline Modified Rankin Score (mRS) at discharge = 1, worsening of condition at discharge (i.e. new neurological deficit or worsening of mRS) = 2 and death in hospital = 3 as dependent variables. LCM was given in dosages of 50-100 mg. It was not earlier administered than as fourth drug. Nevertheless it seemed to be effective for termination of status epilepticus in 20% of the episodes. But the outcome at discharge seemed considerably to depend on age of patients (r = 0.94, explaining 89% of variance).
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epileptic condition. The last AED administered before SE cessation is defined as termination drug, regardless of the latency between its first administration and SE cessation. Cessation of SE is defined as the end of convulsion in EPC and the return to baseline of consciousness or the resolution of previously documented electroencephalographic seizure activity in NCSE. Resolution of seizure activity was diagnosed when spikes, sharp waves or rhythmic waveform showed a frequency below 1 Hz without significant evolution in field, morphology and frequency. 12 As comedication of the termination drug all AEDs given during the 24 h before were listed. Subgroups of NCSE are classified according to the system of Shorvon. 13 Here we present the subset of data concerning the patients treated with LCM. To control for age dependency of results at discharge we calculated a Spearman correlation coefficient with age as independent variable and return to baseline Modified Rankin Score (mRS) 14 at discharge = 1, worsening of condition at discharge (i.e. new neurological deficit or worsening of mRS) = 2 and death in hospital = 3 as dependent variables.
The first two episodes of this series are published as part of a case report of a patient presenting three times with an aphasic status epilepticus after convulsive status epilepticus. 15 The main focus of that paper laid on the diagnostic difficulties in differentiating this semiology of NCSE from a postictal deficit.
Results
Ten episodes of SE (2 EPC, 8 NCSE) in 9 patients (6 female, 3 male) were treated with LCM. Patients' age was 67.1 years on the average (SD 12.4 years). For details of etiology and outcome see Table 1 . The median number of electroencephalograms recorded in each patient was 6 (range 1-10). LCM was not used earlier than as fourth drug (median 6.5, range 4-12) and not earlier than 8 h after onset of symptoms (median 166 h, range 8-637 h). LCM was given intravenously in dosages of 50 mg or 100 mg as a bolus or 50 mg twice a day. No symptomatic bradycardia or other major adverse event was observed. Since most of our patients were in a state of impaired consciousness minor neurotoxic adverse events cannot be ruled out. There were no toxic effects on liver function, renal function or blood cells. In one episode of EPC and one episode of NCSE LCM was the termination drug (episodes 3 + 4). Three patients died in cause of medical complications as pneumonia or septicemia. In one of those patients the NCSE was previously terminated by LCM. In the two other patients NCSE could not be terminated. In all other patients LCM with increased dosage was still a part of the medication at the cessation of SE. For details of medication see Table 2 . In episode 3 propofol was given as anaesthetic but no burst suppression was reached. Under this procedure the interictal electroencephalogram was free of epileptiform patterns but several clinical focal seizures reoccurred until LCM was added to the medication. There was a highly significant correlation between age and outcome (r = 0.94, p < 0.00005) explaining 89% of variance. In fact there was a return to baseline mRS only in patients younger than 60 years, whereas all patients older than 75 years died (see Fig. 1 ).
Discussion
In our group of patients LCM was the termination drug of NCSE or EPC in 20% of the episodes. At first glance this is not in line with 9 It has to be kept in mind that according to all established treatment guidelines we did not give LCM as a first or second line drug in status epilepticus. Since the prognosis of status epilepticus gets worse with each unsuccessful attempt to treat, our data have to be discussed with regard to the place of LCM in the treatment strategies of status epilepticus of other authors. Our successfully treated cases are similar to the case presented by Turpín-Fenoll et al., 8 where a NCSE in a 72-year-old patient was terminated by LCM 25 mg twice a day additionally to levetiracetam 3000 mg after the application of oxcarbacepine, valproate and clobazam had failed. This is the lowest dose of LCM reported to terminate a NCSE and the authors themselves discuss that there might have been a remote effect of the previously given drugs as well. Another case similar to our successfully treated cases was reported by Chen et al. 5 Here EPC was terminated after four days with LCM 50 mg twice a day after lorazepam and loading with phenytoin, levetiracetam and valproate had failed. Since treatment failures are rarely reported as case reports the efficacy of a drug cannot be established on the basis of case reports of successful treatments. Koubeissi et al. 10 claim that they reviewed all adult patients treated with LCM for refractory NCSE at their hospital. They considered each of their four cases as treated successfully. However in their patient two LCM reduced seizure frequency from 2 to 3 seizures per hour to one seizure every 2 h, which would not have qualified for terminating the status in our case series. Nevertheless LCM was given as third or fifth drug with initial doses of 50 mg or 100 mg in a group of patients aged 53-79 years and the condition of all patients somehow improved. This is not in line with our data, but the case series is rather small. In the series of Parkerson et al. 11 LCM was added as second or third agent in 88% of the patients. About 70.5% of their patients improved in terms of seizure frequency or periodic epileptiform activity after administration of LCM. But the outcome at discharge was not so good with four patients being dead and seven being referred to a hospice or a rehabilitation centre. When calculating a spearman correlation between age and clinical outcome with discharge to home = 1, discharge to rehabilitation or hospice = 2 and death = 3 the correlation is r = 0.43 (p = 0.084), which is not significant but may explain about 16% of the variance. The two patients, who were treated with LCM as fourth or fifth drug, were between 60 and 75 years old and outcome was discharge to rehabilitation or hospice. This may be regarded similar to our outcome criteria 2, which was reached by all our patients with an age between 60 and 75. After all LCM like other antiepileptic drugs may be more effective when given early in the course of NCSE and then the influence of age on outcome may be smaller than in our case series. Only Kellinghaus et al. 9 performed a subgroup analysis concerning the time at which LCM was administered in the treatment of NCSE.
In their subgroup of patients, where LCM was given as fourth drug or later, which is comparable to our sample, LCM was the termination drug in three out of 15 patients, which is exactly the 20% as in our group. So in our group of patients LCM seemed to be as effective as in the comparable subgroup of patients in the case series of Kellinghaus et al., 9 though in their study LCM was given at least in the double dosage compared to our study. Because in 2009 no safety data for LCM in higher initial dosages were available in 2009 we preferred the lower dosages as reported here. In all publications about LCM in the treatment of SE the influence of age was not discussed. Elsewhere a negative influence of increasing age on mortality of SE was described several times. 16, 17 But the highly significant association of outcome with age in our group of patients is still striking. Due to the small group of patients this result has to be interpreted with caution. But even with a small sample of n = 10 the 95% confidence interval of a correlation coefficient above 0.9 does not reach 0.6. 18 Therefore with a probability of 95% at least 36% of the variance of the outcome in our group of patients is explained by age. LCM was part of the antiepileptic medication in all surviving patients and may have contributed to the cessation of SE even when it was not the termination drug as defined above. But after all it seems hard to evaluate the efficacy of a drug in a medical condition, where outcome at discharge seems to depend considerably on the age of the patients and not on the therapeutic approach. This has especially to be kept in mind, when prospective studies concerning the therapy of refractory NCSE should be developed. Since in all studies no major side effects clearly attributable to LCM are reported LCM seems to be well tolerated and therefore LCM seems to be a useful alternative in the treatment of refractory NCSE or EPC even when its real efficacy in comparison to levetiracetam, valproate or phenytoin still has to be established. : status not terminated or terminated by anticonvulsant drug other than LCM). Outcome was rated as change of modified Rankin Scale (mRS) score or a new neurological deficit at discharge from hospital compared to mRS score before onset of status epilepticus.
